Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.17 (market cap $39.89B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.54. The key difference: YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GPTY | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $50.52 |
52-Week Low | $278.09 | $34.73 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GPTY trades at $44.48, down 1.16% today, with a bullish technical signal driven by moving averages, though oscillators are neutral. The ETF maintains a consistent weekly dividend distribution strategy, as highlighted in recent YieldMax announcements. Support levels are at $44 and $43, with resistance at $46. Recent news emphasizes its focus on AI and tech exposure combined with option-income strategies.
The outlook for GPTY hinges on its ability to balance high yield with capital preservation in the AI and tech sector. Key risks include heavy reliance on semiconductor momentum and potential NAV erosion from aggressive option strategies. Analyst sentiment is mixed, with some praising its yield approach while others caution on concentration risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
